Uni-Med India Exports Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.20 M
- Company Age 18 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -54.31%
- Ebitda 11.49%
- Net Worth -188.35%
- Total Assets 13.20%
About Uni-Med India Exports
Uni-Med India Exports Private Limited (UIEPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 December 2006 and has a history of 18 years and one month. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Aditi Gvalani, Akshi Gvalani, and Sunil Gvalani serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24239MH2006PTC166437
-
Company No.
166437
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Dec 2006
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Uni-Med India Exports?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akshi Gvalani
|
Director | 22-Nov-2021 | Current |
|
Aditi Gvalani
|
Director | 26-Sep-2017 | Current |
|
Sunil Gvalani
|
Director | 22-Dec-2006 | Current |
Financial Performance of Uni-Med India Exports.
Uni-Med India Exports Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 54.31% decrease in profit. The company's net worth observed a substantial decline by a decrease of 188.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Uni-Med India Exports?
In 2018, Uni-Med India Exports had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Unicliffe Laboratories Private LimitedAditi Gvalani, Akshi Gvalani and 1 more are mutual person
-
Amtrack Laboratories Pvt Ltd
Aditi Gvalani, Akshi Gvalani and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Uni-Med India Exports?
Unlock and access historical data on people associated with Uni-Med India Exports, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Uni-Med India Exports, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Uni-Med India Exports's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
